According to FutureWise analysis the market for Gaucher Disease Treatment in 2023 was US$ 2.1 billion, and is expected to reach US$ 2.51 billion by 2031 at a CAGR of 2.2%.
Gaucher disease (GD) is a metabolic disorder that affects the recycling of cellular glycolipids. It is caused by a lack of the lysosomal enzyme glucocerebrosidase EC3.2.1.45 (also known as glucosyl ceramidase or acid beta-glucosidase [GBA]). In patients with GD, glucosylceramide (also known as glucocerebroside) and several related compounds normally degraded to glucose and lipid components by glucocerebrosidase accumulate within cell lysosomes. Treatment of GD is tailored to the individual patient because of the variability in the manifestations, severity, progression of the disease, and treatment response.GD was the first inherited metabolic disorder to be treated with enzyme replacement therapy (ERT). Additional treatments include substrate reduction therapy (SRT) and supportive care measures to manage associated conditions.
Individuals with Gaucher disease experience different symptoms. Some patients of Gaucher disease exhibit just minor symptoms or none at all. Symptoms in other people can result in critical health issues and even death. Type 2 and 3 of Gaucher's illness also result in neurological (brain) issues in addition to symptoms affecting the blood, organs, and bones. These signs appear within the first six months of life in newborns with Gaucher disease type 2. At birth, they could have abnormalities in their skin. Gaucher disease type 3 symptoms start to show at the age of 10, and they get worse over time. Type 1 Gaucher disease is curable with consistent therapy. For instance, Type 1 treatments either raise enzyme levels or lower the fatty substance that builds up in the body as a result of Gaucher disease. However, the neurological damage caused by types 2 and 3 of Gaucher disease is incurable.
Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Gaucher-Disease-Treatment/10707
Gaucher Disease Treatment Market Segmentation:
By Disease Type
- Type 1 (Neuropathic Forms)
- Type 2 (Perinatal Lethal Form)
- Type 3 (Slow-Neurologic Decay Form)
By Medication
- Enzyme replacement therapy (ERT)
- Imiglucerase (Cerezyme)
- Velaglucerase alfa (VPRIV)
- Taliglucerase alfa (Elelyso)
- Others
- Substrate reduction therapy (SRT)
- Glucosylceramide synthase inhibitors
- Miglustat
- Eliglustat
- Surgical
- Bone marrow transplant
- Spleen Removal
- Glucosylceramide synthase inhibitors
By End User
- Hospitals
- Ambulatory Surgical Centers
- Clinical research institutes
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in Gaucher Disease Treatment Market:
- Abbott
- Aptalis Pharma
- Genzyme Corporation
- GlaxoSmithKline (GSK)
- Pfizer Inc.
- Shire Human Genetic Therapies, Inc.
- Eli Lilly and Company
- Enobia Pharma Inc.
- Anthera Pharmaceuticals, Inc.
- BioMarin Pharmaceutical Inc.
- MedPro Rx
- Zymenex A/S
- Merck Serono
Ask For Discount: https://www.futurewiseresearch.com/contact.aspx?rpt=10707%20type=discount
**Objectives of this Study: **
- To provide a comprehensive analysis of the Gaucher Disease Treatment Market By Disease Type, By Medication, By End User and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
FutureWise Research
Contact Person: Vinay Thaploo.
Email: sales@futurewiseresearch.com
Contact Number: Asia: +91 8605575209 | USA: +1 3477094931
Website: www.futurewiseresearch.com
